{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:33:36Z","timestamp":1789472016382,"version":"build-2803163510"},"reference-count":17,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jaccao.2022.09.003","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T14:04:51Z","timestamp":1671545091000},"page":"649-656","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Burden of Cardiovascular Disease in\u00a0Immune Checkpoint Inhibitor\u2013Treated Patients"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3507-2296","authenticated-orcid":false,"given":"Lavanya","family":"Kondapalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronni","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Flaig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc P.","family":"Bonaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccao.2022.09.003_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs","author":"Haslam","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.jaccao.2022.09.003_bib3","first-page":"35","article-title":"The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity","volume":"3","author":"Zhang","year":"2021","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2022.09.003_bib4","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaccao.2022.09.003_bib5","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1056\/NEJMc1615251","article-title":"Myocarditis with immune checkpoint blockade","volume":"376","author":"Ederhy","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2022.09.003_bib6","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials: race-, sex-, and age-based disparities","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jaccao.2022.09.003_bib7","author":"Bonaca"},{"key":"10.1016\/j.jaccao.2022.09.003_bib8","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jacc.2017.12.048","article-title":"2017 cardiovascular and stroke endpoint definitions for clinical trials","volume":"71","author":"Hicks","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2022.09.003_bib9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2022.09.003_bib10","unstructured":"United States Census Bureau. Accessed June 27, 2021. census.gov\/quickfacts\/CO"},{"key":"10.1016\/j.jaccao.2022.09.003_bib11","series-title":"National Diabetes Statistics Report, 2020","year":"2020"},{"key":"10.1016\/j.jaccao.2022.09.003_bib13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1053\/j.ajkd.2013.03.013","article-title":"Trends in the prevalence of reduced GFR in the United States: a comparison of creatinine- and cystin C-based estimates","volume":"62","author":"Grams","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jaccao.2022.09.003_bib14","unstructured":"Ostchega Y, Fryar CD, Nwankwo T, Nguyen DT. Hypertension Prevalence Among Adults Aged 18 and Over: United States, 2017-2018. NCHS data brief no. 364. National Center for Health Statistics;\u00a02020. https:\/\/www.cdc.gov\/nchs\/data\/databriefs\/db364-h.pdf"},{"key":"10.1016\/j.jaccao.2022.09.003_bib15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jaccao.2022.09.003_bib16","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2022.09.003_bib17","first-page":"137","article-title":"Myocarditis surveillance with high-sensitivity troponin I during cancer treatment with immune checkpoint inhibitors","volume":"3","author":"Waliany","year":"2021","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2022.09.003_bib18","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/cpt.2615","article-title":"Immune checkpoint inhibitors and venous thromboembolism: an analysis of the WHO pharmacovigilance database","volume":"112","author":"Allouchery","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaccao.2022.09.003_bib19","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087322004434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087322004434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T19:07:17Z","timestamp":1727377637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087322004434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2666087322004434"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2022.09.003","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Burden of Cardiovascular Disease in\u00a0Immune Checkpoint Inhibitor\u2013Treated Patients","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2022.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}